Authors

  • Rakhimboyeva G., Akramova D.
  • Mukhammedaminov B.

Keywords:

Parkinson’s disease; parkinsonism plus; GBA; VPS35; genetic mutations.

References

Aharon-Peretz J., Rosenbaum H., Gershoni-Baruch R. Mutations in the glucocerebrosidase gene and Parkinson’s disease. NEJM, 2004; 351: 1972–1977.

Beavan M.S., Schapira A.H. Glucocerebrosidase mutations and the pathogenesis of Parkinson disease. Annals of Medicine, 2013; 45(8): 511–521.

Deng H., Wang P., Jankovic J. The genetics of Parkinson disease. Ageing Research Reviews, 2018; 42: 1–21.

Do C.B., Tung J.Y., Dorfman E. Web-based genome-wide association study identifies two novel loci for Parkinson’s disease. PLoS Genet, 2011; 7(6): e1002141.

Gao J., Huang X., Park Y. Smoking, caffeine intake, and risk of Parkinson disease. Journal of the American Medical Association, 2010; 304(3): 297–303.

Hughes A.J., Daniel S.E., Lees A.J. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology, 2001; 57: 1497–1499.

Malik I., Saeed U., Javed S. VPS35 mutation and its role in Parkinson’s disease pathogenesis. Neuroscience Letters, 2019; 698: 209–215.

Nalls M.A. et al. Large-scale meta-analysis of genome-wide association data identifies new risk loci for Parkinson’s disease. Nature Genetics, 2014; 46: 989–993.

Schapira A.H.V., Gegg M. Mitochondrial contribution to Parkinson’s disease pathogenesis. Parkinsonism & Related Disorders, 2011; 17: S3–S7.

Singleton A.B., Farrer M., Bonifati V. The genetics of Parkinson’s disease: progress and challenges. Human Molecular Genetics, 2013; 22(R1): R9–R15.

Zhang Y., Wu X., Lu Y. GBA mutations and clinical heterogeneity in Parkinson’s disease: a systematic review. Movement Disorders, 2018; 33(8): 1230–1242.